Cubist sales and marketing update

Cubist launched an IV formulation of Sivextro tedizolid in the U.S. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). An oral formulation of the second-generation oxazolidinone that inhibits bacterial protein biosynthesis has been available since June. The wholesale acquisition cost (WAC) for 10 vials containing 200 mg Sivextro is $2,350. The recommended dose is 200 mg once daily for six days. Sivextro has Qualified Infectious Disease Product (QIDP) status for ABSSSI and for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). The designation qualifies Sivextro for an additional five years of market exclusivity. ...